Magnetogastrogram for Gastroparesis
What You Need to Know Before You Apply
What is the purpose of this trial?
There is a tremendous clinical need for a noninvasive technique that can assess gastric electrical activity and would be repeatable without any exposure to radiation. Investigators developed a new technique allowing to use noninvasive methods to assess bioelectrical activity in the gastrointestinal system. This has enabled to characterize the normal and pathologic physiology of the stomach through the use of noninvasive magnetogastrogram (MGG) records. Primary hypothesis for this proposal is that analysis of gastric slow wave uncoupling and propagation in multichannel MGG discriminates between normal and pathological gastric electrical activity. Eventually, investigators envision this research leading to new insights for gastrointestinal conditions such as gastroparesis, functional dyspepsia and chronic idiopathic nausea that would inform clinical management of these debilitating diseases.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.
Is the Magnetogastrogram safe for humans?
The safety of magnetopharmaceuticals, like gadopentetate dimeglumine used in MRI, is generally good with most adverse effects being minor and temporary, such as nausea and vomiting. Severe reactions are rare, occurring in about 1 in 350,000 to 450,000 cases, and are less common than with other contrast agents.12345
How does the magnetogastrogram treatment for gastroparesis differ from other treatments?
The magnetogastrogram (MGG) treatment for gastroparesis is unique because it is a non-invasive method that evaluates gastric magnetic field activity, unlike traditional methods that assess electrical activity and are affected by body mass index. MGG provides reliable and reproducible measurements of gastric emptying, making it a promising alternative to the current gold standard, scintigraphy, for assessing gastric motility.678910
Who Is on the Research Team?
Leonard A Bradshaw, PhD
Principal Investigator
Vanderbilt University Medical Center
Are You a Good Fit for This Trial?
This trial is for people aged 12-80 with conditions like gastroparesis, chronic nausea, or those who've had a gastrectomy. It includes diabetic patients and children with functional dyspepsia. Pregnant women, individuals over 80, those with claustrophobia, morbid obesity, cardiac arrhythmias or on anticoagulants cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo noninvasive magnetogastrogram (MGG) to assess gastric electrical activity
Follow-up
Participants are monitored for changes in gastric electrical activity and symptoms
What Are the Treatments Tested in This Trial?
Interventions
- Magnetogastrogram
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator